Theophylline ER ( DrugBank: Theophylline )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 236 | 偽性副甲状腺機能低下症 | 1 |
236. 偽性副甲状腺機能低下症
臨床試験数 : 6 / 薬物数 : 4 - (DrugBank : 2) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04240821 (ClinicalTrials.gov) | May 22, 2020 | 21/1/2020 | Theophylline for Treatment of Pseudohypoparathyroidism | Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism | Pseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline ER | Ashley Shoemaker | NULL | Enrolling by invitation | 2 Years | 99 Years | All | 34 | Phase 2 | United States |